Clinical Trial Update: A Phase I/II Clinical Trial of PXD101 in Combination With Doxorubicin in Patients With Soft Tissue Sarcomas [Phase 1, Phase 2]

View source ↗

Summary

Phase I/II study evaluating panobinostat (PXD101) in combination with doxorubicin for soft tissue sarcoma; the trial completed with results posted in 2014.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Soft Tissue Sarcoma

Drugs mentioned

• Doxorubicin (doxorubicin)
• PXD101

Snippet

Sponsor: Valerio Therapeutics | Conditions: Dose Escalation: Solid Tumors, MTD: Soft Tissue Sarcomas | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2014-12-29